XML 35 R25.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Significant Segment Expenses | The following table is a summary of the Company's significant segment expenses:
|  |  |  |  | Three months ended June 30, 2025 |  | Three months ended June 30, 2024 |  | Change
Direct research and development expenses: |  |  |  |  |  |  |  |  |
VTP-1000 Celiac |  |  |  |  | $ | 1,782 |  |  | $ | 1,371 |  |  | $ | 411 |
VTP-300 HBV |  |  |  |  | 1,837 |  |  | 3,034 |  |  | (1,197) |
Other clinical programs 1 |  |  |  |  | 642 |  |  | 1,125 |  |  | (483) |
Other pre-clinical programs |  |  |  |  | 449 |  |  | 908 |  |  | (459) |
Total direct research and development expenses |  |  |  |  | 4,710 |  |  | 6,438 |  |  | (1,728) |
Indirect research and development expenses: |  |  |  |  |  |  |  |  |
Personnel-related (including share-based compensation)2 |  |  |  |  | 2,450 |  |  | 4,763 |  |  | (2,313) |
Facility related |  |  |  |  | 350 |  |  | 342 |  |  | 8 |
Other indirect costs |  |  |  |  | 443 |  |  | 119 |  |  | 324 |
Total indirect research and development expenses |  |  |  |  | 3,243 |  |  | 5,224 |  |  | (1,981) |
Total research and development expenses |  |  |  |  | $ | 7,953 |  |  | $ | 11,662 |  |  | $ | (3,709) |
|  |  |  |  | Six months ended June 30, 2025 |  | Six months ended June 30, 2024 |  | Change
Direct research and development expenses: |  |  |  |  |  |  |  |  |
VTP-1000 Celiac |  |  |  |  | $ | 2,764 |  |  | $ | 2,744 |  |  | $ | 20 |
VTP-300 HBV |  |  |  |  | 3,187 |  |  | 4,947 |  |  | (1,760) |
Other clinical programs 1 |  |  |  |  | 1,383 |  |  | 2,893 |  |  | (1,510) |
Other pre-clinical programs |  |  |  |  | 868 |  |  | 1,693 |  |  | (825) |
Total direct research and development expenses |  |  |  |  | 8,202 |  |  | 12,277 |  |  | (4,075) |
Indirect research and development expenses: |  |  |  |  |  |  |  |  |
Personnel-related (including share-based compensation)2 |  |  |  |  | 6,394 |  |  | 9,097 |  |  | (2,703) |
Facility related |  |  |  |  | 685 |  |  | 732 |  |  | (47) |
Other indirect costs |  |  |  |  | 962 |  |  | 681 |  |  | 281 |
Total indirect research and development expenses |  |  |  |  | 8,041 |  |  | 10,510 |  |  | (2,469) |
Total research and development expenses |  |  |  |  | $ | 16,243 |  |  | $ | 22,787 |  |  | $ | (6,544) |
1 This includes expenses relating to the infectious disease and oncology programs; VTP-850 Prostate cancer, VTP-200 HPV, VTP-600 NSCLC (the Phase 1/2a trial is sponsored by Cancer Research UK) and VTP-500 MERS (funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”). Expenses relating to these programs were previously presented separately, but are now aggregated for the prior period comparative.
2 This includes $0.1 million and $0.1 million for the three and six months ended June 30, 2025, respectively (three and six months ended June 30, 2024:$0.2 million and $0.3 million, respectively) of personnel-related indirect expenses relating to time spent progressing the VTP-500 MERS program, which is funded by CEPI.
Schedule of Long-Lived Assets | The Company operates in two geographic regions: the U.S. and the U.K. The following table summarizes the Company’s assets held for sale and long-lived assets, which include the Company’s intangible assets, property and equipment, net, and right-of-use assets, by geography:
| June 30, 2025 |  | December 31, 2024
United States | $ | 26,845 |  |  | $ | 28,907 |
United Kingdom | 1,771 |  |  | 4,797 |
| $ | 28,616 |  |  | $ | 33,704 |

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration